Key facts
- Actithera’s last known valuation is $110.0M (Jul 2025).
- It has raised $80.8M; the latest was Early Stage VC ($75.5M) in Jul 2025.
- Notable investors include Sofinnova Partners, Innovestor, M Ventures, Arkin Capital, Surveyor Capital — 10 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 10 names
- ·Watchlist + deal alerts for Actithera
- ·The full record, as it builds
Funding rounds
No funding rounds for Actithera are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Actithera
Operator of a molecular radio therapeutic company intended for biotechnology research services. The company focuses on improving cancer treatment through utilizing radioactive isotopes linked to specific molecules, aiming for precise delivery of radiation directly to cancer cells with an aim to develop radiopharmaceuticals, enabling consumers to get focused radiation for cancer cells while minimizing harm to healthy tissues.
- Sector
- Healthcare
- HQ
- Cambridge, MA, United States
- Founded
- 2021
- Employees
- 3
- Website
- actithera.com/
- Ownership
- Privately Held (backing)
Actithera doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Actithera shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Actithera in its N-PORT filings yet. We sweep new filings monthly.